Almost all severely allergic people could complete 2 dose COVID vaccine protocol: JAMA
BOSTON - Nearly all healthcare workers at a Boston healthcare system who reported severe allergic reactions after receiving a COVID-19 mRNA vaccine were able to safely complete the series.
The study of employee vaccinations within the Mass General Brigham health care system revealed that although people with such a history reported more allergic symptoms after vaccination, nearly all of them were able to become fully vaccinated.
New research addressing ongoing concerns regarding risks of allergic reactions after receiving mRNA COVID-19 vaccines, particularly for individuals with a history of severe allergic reactions has been published in the JAMA Network Open.
In the study of 52,998 health care employees, 474 (0.9%) reported a history of severe allergic reactions to medications, vaccines or allergens. Survey results showed that 11.6% of employees with this history reported allergic reactions after receiving dose 1 or 2 of a COVID-19 mRNA vaccine, compared with 4.7% of employees without this history. High-risk allergy history was associated with a 2.5-times increased relative risk of allergic reactions, with the highest risks for hives and angioedema. However, despite these symptoms, 5,1706 employees (97.6%) received 2 doses of an mRNA COVID-19 vaccine.
"The results of this study can help guide expectations for patients with high-risk allergy histories. Symptoms such as hives and swelling may occur, particularly with the first vaccine dose, but most reported allergic symptoms did not impede completion of the two-dose mRNA vaccine series," says lead author Lily Li, MD, allergy faculty in the Division of Allergy and Clinical Immunology at Brigham and Women's Hospital.
The findings provide reassurance regarding the safety of mRNA COVID-19 vaccination in individuals regardless of allergy history. "We hope these data will help inform ongoing conversations with patients who are hesitant to receive COVID-19 vaccination due to allergy concerns," says senior author author Kimberly G. Blumenthal, MD, MSc, co-director of the Clinical Epidemiology Program within Massachusetts General Hospital's Division of Rheumatology, Allergy and Immunology. "At our institutions, nearly all individuals with and without a history of high-risk allergy were able to complete the two-dose vaccine series."
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2785466
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.